Efficacy and Safety of Somatropin in Adult Patients on Chronic Haemodialysis
Efficacy and Safety of Somatropin in Adult Patients on Chronic Haemodialysis
This trial is conducted in Africa, Asia, Europe, North and South America and Oceania.
The aim of the trial is to evaluate the effect of somatropin (human growth hormone) on survival (primary end-point; "time to death" and health related quality of life in adult patients on chronic haemodialysis.
The decision to discontinue the trial is not due to safety concerns. The discontinuation is based on an analysis of the significant delay in recruitment of patients which is expected to have a negative impact on the outcome of the trial.
Inclusion Criteria:
Exclusion Criteria:
Tuscon, Arizona 85723, United States
Lafayatte, Louisiana 70506, United States
Capital Federal, C1425BPM, Argentina
Capital Federal, C1431FWO, Argentina
Jaboatao de Guararapes, 54400-170, Brazil
São José Rio Preto, 15090-000, Brazil
Arhus N, 8200, Denmark
Hilleroed, 3400, Denmark
Cherbourt-Octeville, 50102, France
Hyderabad, Andhra Pradesh 500082, India
Tzriffin, 70300, Israel
Poznann, 60-355, Poland
Ul Mlynska 5, 33-300, Poland
Villa Franca de Xira, 2600-076, Portugal
Villa Nova de Gaia, 4430-196, Portugal
Obervatory, 7925, South Africa